Nektar Therapeutics

NKTR
Delayed Nasdaq - 03/20 09:00:00 pm
32.61USD
-5.23%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20182019
Sales1 193119
EBITDA699-524
Operating profit (EBIT)688-499
Pre-Tax Profit (EBT)--
Net income681-500
EPS ( $ )3,78-2,83
Dividend per Share ( $ )--
Yield--
Announcement Date02/28/2019
09:10pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20182019
Debt--
Finance1 0881 671
Operating income (EBITDA)699-524
Leverage
(Debt/EBITDA)
--
Capital Expenditure14,210,1
Book Value Per Share (BVPS)10,8 $10,5 $
Cash Flow per Share4,64 $-2,57 $
Announcement Date02/28/2019
09:10pm
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 5 678 M$ -
Entreprise Value (EV) 4 007 M$ 4 964 M$
Valuation 2019e 2020e
P/E ratio (Price / EPS)
Capitalization / Revenue 47,8x 26,1x
EV / Revenue 33,8x 22,8x
EV / EBITDA -7,65x -11,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,10x 3,78x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -421% -186%
operating Leverage (Delta EBIT / Delta Sales) -1,92x 0,23x
Net Margin (Net Profit / Revenue) -421% -181%
ROA (Net Profit / Asset) -29,2% -20,4%
ROE (Net Profit / Equities) -38,1% -26,6%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   8,51% 5,30%
Cash Flow / Sales -377% -211%
Capital Intensity (Assets / Sales) 14,4x 8,91x
Financial Leverage (Net Debt / EBITDA) 3,19x 1,61x
Price Earning Ratio
BNA & Dividende